

## Highly Specialised Technologies Evaluation Committee Interests Register

**Topic: Nivolumab with ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]**

**Publication Date: 28 May 2025**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
<b>Stuart Mealing</b>	HST Committee Member	<b>Non-Financial Professional interests</b>	The company Stuart works for has undertaken some non-product or indication specific methods work funded by BMS.	13/12/2024 13/03/2025	It was agreed that Stuart's declaration would not prevent them from participating in discussions on this appraisal.
<b>Jenny Seligmann</b>	Clinical Expert	<b>Direct – financial interests</b>	Jenny attended an Advisory Board funded by BMS (£4500).	16/01/2025 13/03/2025	It was agreed that Jenny's declaration would not prevent them from providing expert advice to the committee.
<b>Richard Wilson</b>	Clinical Expert	<b>Direct – financial interests</b>	Richard declared the following interests: <ul style="list-style-type: none"> <li>Bristol-Myers Squibb – I have received honoraria for 2 UK advisory board meetings with BMS where we discussed (i) management of dMMR/MSI-High colorectal cancer in the UK, and (ii) landscape of management of metastatic colorectal</li> </ul>	16/01/2025 13/03/2025	It was agreed that Richard's declaration would not prevent them from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>cancer through all lines of therapy in the UK. These were broadly based and part of BMS wishing to understand different aspects of how colorectal cancer is managed across the UK, including regional and devolved nation differences.</p> <ul style="list-style-type: none"> <li>• Amgen - I received an honorarium for advisory board attendance discussing the use of biomarkers in advanced cancers including colorectal cancer</li> <li>• Merckgroup - I received an honorarium and travel and accommodation expenses for chairing a UK educational meeting on metastatic colorectal cancer</li> </ul>		